ISDA

Deposition Date 2013-10-18

Release Date 2014-09-03

Last Version Date 2024-11-06

Entry Detail

PDB ID:

4N90

Keywords:

Apoptosis/Immune System

Title:

Crystal structure of ternary complex of TRAIL, DR5, and Fab fragment from a DR5 agonist antibody

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

3.30 Å

R-Value Free:

0.28

R-Value Work:

0.22

Space Group:

P 61 2 2

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Tumor necrosis factor ligand superfamily member 10
Gene (Uniprot):TNFSF10
Chain IDs:D (auth: A), E (auth: B), F (auth: C)
Chain Length:168
Number of Molecules:3
Biological Source:Homo sapiens

UniProt ID:P50591 Pfam ID:PF00229

Polymer Type:polypeptide(L)
Molecule:Fab heavy chain
Chain IDs:H (auth: D), J (auth: F), L (auth: H)
Chain Length:224
Number of Molecules:3
Biological Source:Homo sapiens

Polymer Type:polypeptide(L)
Molecule:Fab light chain
Chain IDs:G (auth: E), I (auth: G), K (auth: I)
Chain Length:215
Number of Molecules:3
Biological Source:Homo sapiens

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Tumor necrosis factor receptor superfamily member 10B
Gene (Uniprot):TNFRSF10B
Chain IDs:A (auth: R), B (auth: S), C (auth: T)
Chain Length:126
Number of Molecules:3
Biological Source:Homo sapiens

UniProt ID:O14763 Pfam ID:PF00020

Ligand Molecules

Primary Citation

Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity.

Graves, J.D, Kordich, J.J, Huang, T.H, Piasecki, J, Bush, T.L, Sullivan, T, Foltz, I.N, Chang, W, Douangpanya, H, Dang, T, O'Neill, J.W, Mallari, R, Zhao, X, Branstetter, D.G, Rossi, J.M, Long, A.M, Huang, X, Holland, P.M.Show

Cancer Cell 26 177 189 (2014)

PMID: 25043603 DOI: 10.1016/j.ccr.2014.04.028

Abstact

Death receptor agonist therapies have exhibited limited clinical benefit to date. Investigations into why Apo2L/TRAIL and AMG 655 preclinical data were not predictive of clinical response revealed that coadministration of Apo2L/TRAIL with AMG 655 leads to increased antitumor activity in vitro and in vivo. The combination of Apo2L/TRAIL and AMG 655 results in enhanced signaling and can sensitize Apo2L/TRAIL-resistant cells. Structure determination of the Apo2L/TRAIL-DR5-AMG 655 ternary complex illustrates how higher order clustering of DR5 is achieved when both agents are combined. Enhanced agonism generated by combining Apo2L/TRAIL and AMG 655 provides insight into the limited efficacy observed in previous clinical trials and suggests testable hypotheses to reconsider death receptor agonism as a therapeutic strategy.

Legend

Protein

Chemical

Disease

Primary Citation of related structures